ClinicalTrials.gg
CompletedNCT02205606Updated Sep 22, 2015

Efficacy/Safety of HCP1306 Tablet Versus HGP0816 Tablet in Patients With Primary Hypercholesterolemia

A Phase 3 interventional study of HGP0816 5mg and HGP0816 10mg in Primary Hypercholesterolemia, sponsored by Hanmi Pharmaceutical Company Limited. Completed at 1 site in Korea, Republic of. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2015-09-22.

Sponsored by Hanmi Pharmaceutical Company Limited · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
412
Allocation
Randomized
Ages
19 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 81 studies in Hypercholesterolemia with a site in Korea, Republic of — 6 open to participants now, 11 under way, 5 of them phase 3. Hypercholesterolemia · Korea, Republic of.

Enrollment
17th of 66
412 · median 251
Started
2014
with 5 others
Phase 3
35 of 81
1 open now
Registered
32nd of 81
by date

Among the 81 studies in Hypercholesterolemia with a site in Korea, Republic of, this one is the 17th largest by enrollment of the 66 interventional ones that give a count, is one of 6 that started in 2014, is one of 35 in phase 3, and was the 32nd registered.

Hypercholesterolemia

1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.

Browse Hypercholesterolemia studies →

Open to participants now

6 of the 81 studies in Hypercholesterolemia with a site in Korea, Republic of are open now. Recruiting first, the newest first:

1 more — sign in →

All 6 open studies →

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 55 Hypercholesterolemia studies recruiting now, 23 (42%) set no upper age limit and 20 (36%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.

This study: 19 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 81 studies in Hypercholesterolemia with a site in Korea, Republic of, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate efficacy and safety of HCP1306 in patients with primary hypercholesterolemia.

03

Conditions studied

  • Primary Hypercholesterolemia
04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged over 19 years
  • Signed
  • At visit 1, LDL-C ≤ 250mg/dL and Triglyceride \< 400 mg/dL
  • After 4 weeks more TLC, At visit2, LDL-C ≤ 250mg/dL, Triglyceride \< 400 mg/dL and satisfied criteria according to Risk of cardiovascular disease

Exclusion criteria

Exclusion Criteria:

  • Current or past history of to HMG-CoA reductase inhibitors and component of Ezetimibe
  • Has an active liver disease and severe liver disorder (continous elevation of , ALT level or exceeds more than 3 times of normal upper limit)
  • Has a severe renal failure and kidney injury (Creatinine level exceeds more than 2 times of normal upper limit)
  • CK level exceeds more than 5 times of normal upper limit
  • Uncontrolled hypertension patient (SBP≥ 180 mmHg or DBP ≥ 110 mmHg)
  • Uncontrolled diabetes mellitus patient ( ≥ 9%)
  • Uncontrolled malfunctional thyroidism (or at pre-visit 2, TSH level exceeds more than 1.5 times of normal upper limit)
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
412 participants (actual)

Study arms

  • Active comparator
    HGP0816 5mg

    Drug: HGP0816 5mg

  • Active comparator
    HGP0816 10mg

    Drug: HGP0816 10mg

  • Active comparator
    HGP0816 20mg

    Drug: HGP0816 20mg

  • Experimental
    HCP1306 5/10mg

    Drug: HCP1306 5/10mg

  • Experimental
    HCP1306 10/10mg

    Drug: HCP1306 10/10mg

  • Experimental
    HCP1306 20/10mg

    Drug: HCP1306 20/10mg

Interventions

06

What researchers measure

Primary outcomes

  1. Percent change from baseline to 8 week in LDL-Cholesterol

    Time frame: baseline and 8 week

Secondary outcomes

  1. Percent change from baseline to 4 week in LDL-Cholesterol

    Time frame: baseline and 4 week

  2. Percentage of patients reaching treatment goals according to NCEP ATP III Guideline

    Time frame: week 4, week 8

  3. Percent change from baseline to 4 week and 8 week in TC

    Time frame: week 4, week 8

  4. Percent change from baseline to 4 week and 8 week in HDL-C

    Time frame: week 4, week 8

  5. Percent change from baseline to 4 week and 8 week in TG

    Time frame: week 4, week 8

07

Study locations

1 site
  • 19 institutions including Seoul National University Hospital
    Seoul, Korea, Republic of
08

References and documents

Publications

  • Rhee MY, Kim KJ, Kim SH, Yoon YW, Rha SW, Hong SJ, Kwak CH, Kim W, Nam CW, Park TH, Hong TJ, Park S, Ahn Y, Lee N, Jeon HK, Jeon DW, Han KR, Moon KW, Chae IH, Kim HY, Kim HS. Ezetimibe and Rosuvastatin Combination Treatment Can Reduce the Dose of Rosuvastatin Without Compromising Its Lipid-lowering Efficacy. Clin Ther. 2019 Dec;41(12):2571-2592. doi: 10.1016/j.clinthera.2019.10.010. Epub 2019 Nov 11. PubMed 31727361 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2014, a primary completion of Feb 2015 and a completion of Apr 2015. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 30, 2014
First posted
Jul 31, 2014
Start
Jun 2014
Primary completionActual
Feb 2015
CompletionActual
Apr 2015
Last update
Sep 22, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 22, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02205606
Responsible party
Sponsor
First posted
Jul 31, 2014
Start date
Jun 2014
Primary completion
Feb 2015
Completion
Apr 2015
Last update
Sep 22, 2015

Study contacts

Hyo-soo Kim, MD, Ph.D.
principal investigator · Seoul National University Hospital

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: HGP0816

Start the discussion